A randomized phase 3b study evaluating safety and efficacy of risankizumab in adult patients with moderate-to-severe plaque psoriasis with non-pustular palmoplantar involvement

Published: 22 July 2024| Version 1 | DOI: 10.17632/szpjbkj48j.1
Contributors:
Mark Lebwohl, Michael Bukhalo, Linda Stein Gold, Brad Glick, Mar Llamas Velasco, Samuel Sanchez-Rivera, Anqi Pan, Tianyu Zhan, Leonidas Drogaris, Kevin Douglas, Greg St. John, Ramon Espaillat, Robert Bissonnette

Description

This IMMprint study aimed to evaluate the safety and efficacy of risankizumab (RZB) compared to a placebo for the treatment of non pustular palmoplantar psoriasis (PPPsO). The study involved randomizing patients to receive either RZB or placebo for 16 weeks, followed by continued RZB treatment until week 52. RZB showed significant efficacy compared to the placebo at week 16 in terms of achieving clear or almost clear skin, improvement in the severity of palmoplantar psoriasis, and improved physician assessment. The results continued to improve through week 52, and no new safety concerns were identified. However, the study did not compare RZB to other biologic treatments. In conclusion, RZB demonstrated both safety and efficacy for the treatment of PPPsO.

Files

Categories

Psoriasis

Funding

AbbVie

Licence